2004 in cancer

FDA · US: 38 records / 16 drugsEMA · EU: 7 records / 7 drugsHealth Canada · CA: 6 records / 6 drugs

• Dec 14, 2004Leuprolide FDA · US original application approved Malignant Prostate NeoplasmVABRINTY is indicated for the treatment of advanced prostate cancer. VABRINTY is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of…openfda
• May 19, 2004Azacitidine FDA · US original application approved Juvenile Myelomonocytic LeukemiaPediatric patients aged 1 month and older with newly diagnosed Juvenile Myelomonocytic Leukemia (JMML).openfda
• Apr 28, 2004Fludarabine FDA · US original application approved Chronic Lymphocytic LeukemiaFludarabine Phosphate Injection is a nucleotide metabolic inhibitor indicated for: The treatment of adult patients with B-cell chronic lymphocytic leukemia…openfda
• Mar 8, 2004Cinacalcet FDA · US original application approved Parathyroid CarcinomaLimitations of Use: Sensipar is not indicated for use in patients with CKD who are not on dialysis Hypercalcemia in adult patients with Parathyroid Carcinoma…openfda
• Feb 26, 2004Bevacizumab FDA · US original application approved Malignant Peritoneal NeoplasmEpithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for…openfda
• Feb 26, 2004Bevacizumab FDA · US original application approved GlioblastomaRecurrent glioblastoma in adults.openfda
• Feb 26, 2004Bevacizumab FDA · US original application approved Renal Cell CarcinomaMetastatic renal cell carcinoma in combination with interferon alfa.openfda
• Feb 26, 2004Bevacizumab FDA · US original application approved Hepatocellular CarcinomaHepatocellular Carcinoma (HCC) in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior…openfda
• Feb 26, 2004Bevacizumab FDA · US original application approved Malignant Colon NeoplasmLimitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer.openfda
• Feb 26, 2004Bevacizumab FDA · US original application approved Malignant Cervical NeoplasmPersistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan.openfda
• Feb 26, 2004Bevacizumab FDA · US original application approved Lung Non-Squamous Non-Small Cell CarcinomaUnresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line…openfda
• Feb 26, 2004Bevacizumab FDA · US original application approved Malignant Colorectal NeoplasmMetastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.openfda
• Feb 26, 2004Bevacizumab FDA · US original application approved Malignant Colorectal NeoplasmMetastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in…openfda
• Feb 12, 2004Cetuximab FDA · US original application approved Head and Neck Squamous Cell CarcinomaRecurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil.openfda
• Feb 12, 2004Cetuximab FDA · US original application approved Malignant Colorectal NeoplasmColorectal Cancer K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI for…openfda
• Feb 12, 2004Cetuximab FDA · US original application approved Head and Neck Squamous Cell CarcinomaHead and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy.openfda
• Feb 12, 2004Cetuximab FDA · US original application approved Malignant Colorectal NeoplasmLimitations of Use: ERBITUX is not indicated for treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown. ( 5.7 )…openfda
• Feb 12, 2004Cetuximab FDA · US original application approved Head and Neck Squamous Cell CarcinomaRecurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy.openfda
• Feb 4, 2004Pemetrexed FDA · US original application approved Lung Non-Squamous Non-Small Cell Carcinomaas a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four…openfda
• Feb 4, 2004Pemetrexed FDA · US original application approved Pleural Malignant Mesotheliomainitial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not…openfda
• Feb 4, 2004Pemetrexed FDA · US original application approved Lung Non-Small Cell CarcinomaLimitations of Use: ALIMTA is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer.openfda
• Feb 4, 2004Pemetrexed FDA · US original application approved Lung Non-Squamous Non-Small Cell Carcinomaas a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.openfda
• Feb 4, 2004Pemetrexed FDA · US original application approved Lung Non-Squamous Non-Small Cell Carcinomain combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer…openfda
• Feb 4, 2004Pemetrexed FDA · US original application approved Lung Non-Squamous Non-Small Cell Carcinomain combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.openfda
• Jun 1, 2004Meloxicam FDA · US original application approved cancer not stated in this recordOsteoarthritis (OA) • Rheumatoid Arthritis (RA) • Juvenile Rheumatoid Arthritis (JRA) in patients 2 years of age or olderopenfda
• May 19, 2004Azacitidine FDA · US original application approved cancer not stated in this recordAdult patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if…openfda
• Mar 8, 2004Cinacalcet FDA · US original application approved cancer not stated in this recordSecondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. • Hypercalcemia in adult patients with primary HPT for…openfda
• Feb 26, 2004Bevacizumab FDA · US original application approved cancer not stated in this recordin combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior…openfda
• Apr 28, 2004Mitotane EMA · EU centralised approved Adrenal Cortical CarcinomaSymptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical…ema
• Apr 14, 2004Cladribine EMA · EU centralised approved Hairy Cell LeukemiaLitak is indicated for the treatment of hairy-cell leukaemia.ema
• Mar 9, 2004Fulvestrant EMA · EU centralised approved Malignant Breast NeoplasmFaslodex is indicated as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: not…ema
• Dec 10, 2004Anagrelide FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2004-12-10 (see label)openfda
• Nov 15, 2004Anagrelide EMA · EU centralised approved cancer not stated in this recordXagrid is indicated for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (ET) patients who are intolerant to their current…ema
• Oct 29, 2004Letrozole FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2004-10-29 (see label)openfda
• Oct 27, 2004Doxorubicin FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2004-10-27 (see label)openfda
• Oct 25, 2004Imatinib Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as GLEEVEC (DIN 02253283) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Oct 22, 2004Ibritumomab Tiuxetan FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2004-10-22 (see label)openfda
• Sep 20, 2004Pemetrexed EMA · EU centralised approved cancer not stated in this recordMalignant pleural mesothelioma Alimta in combination with cisplatin is indicated for the treatment of chemotherapy-naïve patients with unresectable malignant…ema
• Aug 19, 2004Sertraline FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2004-08-19 (see label)openfda
• Aug 19, 2004Sertraline FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2004-08-19 (see label)openfda
• Aug 18, 2004Docetaxel FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2004-08-18 (see label)openfda
• Jun 29, 2004Cetuximab EMA · EU centralised approved cancer not stated in this recordErbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer: in…ema
• Jun 24, 2004Irinotecan FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2004-06-24 (see label)openfda
• Jun 14, 2004Fulvestrant Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as FASLODEX (DIN 02248624) under ATC L02BA03 FULVESTRANT. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Jun 3, 2004Aminolevulinic Acid Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as LEVULAN KERASTICK (DIN 02243933) under ATC L01XD04 AMINOLEVULINIC ACID. Indications are not published in the Drug Product Database — see…health-canada-dpd
• May 19, 2004Docetaxel FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2004-05-19 (see label)openfda
• Apr 29, 2004Leuprolide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as ELIGARD (DIN 02248999) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
• Apr 26, 2004Bortezomib EMA · EU centralised approved cancer not stated in this recordVelcade as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with…ema
• Apr 12, 2004Methotrexate Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as METHOTREXATE TABLETS, USP (DIN 02182750) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see…health-canada-dpd
• Mar 26, 2004Interferon Beta-1a FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2004-03-26 (see label)openfda
• Mar 12, 2004Pegfilgrastim Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as NEULASTA (DIN 02249790) under ATC L03AA13 PEGFILGRASTIM. Indications are not published in the Drug Product Database — see the Health…health-canada-dpd

RegulatoryAll 2004 records with filters →

Studies

2,252

Interventional

2,203

Phase III

383

Industry-led

410

With posted results

224

Countries with sites

74

Published source: clinicaltrials · first_posted_date as posted